These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

141 related articles for article (PubMed ID: 11263525)

  • 1. Risk factors for hepatotoxicity during anti-tuberculosis chemotherapy in Asian populations.
    Yew WW
    Int J Tuberc Lung Dis; 2001 Jan; 5(1):99-100. PubMed ID: 11263525
    [No Abstract]   [Full Text] [Related]  

  • 2. Slow N-acetyltransferase 2 genotype affects the incidence of isoniazid and rifampicin-induced hepatotoxicity.
    Ohno M; Yamaguchi I; Yamamoto I; Fukuda T; Yokota S; Maekura R; Ito M; Yamamoto Y; Ogura T; Maeda K; Komuta K; Igarashi T; Azuma J
    Int J Tuberc Lung Dis; 2000 Mar; 4(3):256-61. PubMed ID: 10751073
    [TBL] [Abstract][Full Text] [Related]  

  • 3. DNA microarray genotyping of N-acetyltransferase 2 polymorphism using carbodiimide as the linker for assessment of isoniazid hepatotoxicity.
    Shimizu Y; Dobashi K; Mita Y; Endou K; Moriya S; Osano K; Koike Y; Higuchi S; Yabe S; Utsugi M; Ishizuka T; Hisada T; Nakazawa T; Mori M
    Tuberculosis (Edinb); 2006 Sep; 86(5):374-81. PubMed ID: 16246623
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Susceptibility of N-acetyltransferase 2 slow acetylators to antituberculosis drug-induced liver injury: a meta-analysis.
    Shi J; Xie M; Wang J; Xu Y; Liu X
    Pharmacogenomics; 2015 Dec; 16(18):2083-97. PubMed ID: 26616266
    [TBL] [Abstract][Full Text] [Related]  

  • 5. CYP2E1 genotype and isoniazid-induced hepatotoxicity in patients treated for latent tuberculosis.
    Vuilleumier N; Rossier MF; Chiappe A; Degoumois F; Dayer P; Mermillod B; Nicod L; Desmeules J; Hochstrasser D
    Eur J Clin Pharmacol; 2006 Jun; 62(6):423-9. PubMed ID: 16770646
    [TBL] [Abstract][Full Text] [Related]  

  • 6. NAT2 genotype guided regimen reduces isoniazid-induced liver injury and early treatment failure in the 6-month four-drug standard treatment of tuberculosis: a randomized controlled trial for pharmacogenetics-based therapy.
    Azuma J; Ohno M; Kubota R; Yokota S; Nagai T; Tsuyuguchi K; Okuda Y; Takashima T; Kamimura S; Fujio Y; Kawase I;
    Eur J Clin Pharmacol; 2013 May; 69(5):1091-101. PubMed ID: 23150149
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pharmacogenetic association between
    Khan S; Mandal RK; Elasbali AM; Dar SA; Jawed A; Wahid M; Mahto H; Lohani M; Mishra BN; Akhter N; Rabaan AA; Haque S
    Biosci Rep; 2019 Jan; 39(1):. PubMed ID: 30509962
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A case series of three patients presenting with isoniazid induced toxicity and N-acetyl transferase 2 gene mutation: A management conundrum for programmatic therapy of tuberculosis in India.
    Shetty P; Panchal F; Munshi R; Sundar U; Darole P
    Indian J Tuberc; 2020 Jul; 67(3):407-410. PubMed ID: 32825881
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Tuberculosis: relevance of isoniazid dosage in prevention of liver side effects].
    Negri L; Le Grusse J; Séraissol P; Lavit M; Houin G; Gandia P
    Therapie; 2014; 69(6):509-16. PubMed ID: 25314930
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Determining the relation between N-acetyltransferase-2 acetylator phenotype and antituberculosis drug induced hepatitis by molecular biologic tests.
    Bozok Cetintaş V; Erer OF; Kosova B; Ozdemir I; Topçuoğlu N; Aktoğu S; Eroğlu Z
    Tuberk Toraks; 2008; 56(1):81-6. PubMed ID: 18330759
    [TBL] [Abstract][Full Text] [Related]  

  • 11. N-acetyltransferase 2 polymorphisms and risk of anti-tuberculosis drug-induced hepatotoxicity in Caucasians.
    Leiro-Fernandez V; Valverde D; Vázquez-Gallardo R; Botana-Rial M; Constenla L; Agúndez JA; Fernández-Villar A
    Int J Tuberc Lung Dis; 2011 Oct; 15(10):1403-8. PubMed ID: 22283902
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Genetic polymorphisms of NAT2, CYP2E1 and GST enzymes and the occurrence of antituberculosis drug-induced hepatitis in Brazilian TB patients.
    Teixeira RL; Morato RG; Cabello PH; Muniz LM; Moreira Ada S; Kritski AL; Mello FC; Suffys PN; Miranda AB; Santos AR
    Mem Inst Oswaldo Cruz; 2011 Sep; 106(6):716-24. PubMed ID: 22012226
    [TBL] [Abstract][Full Text] [Related]  

  • 13. N-acetyl transferase 2 and cytochrome P450 2E1 genes and isoniazid-induced hepatotoxicity in Brazilian patients.
    Santos NP; Callegari-Jacques SM; Ribeiro Dos Santos AK; Silva CA; Vallinoto AC; Fernandes DC; de Carvalho DC; Santos SE; Hutz MH
    Int J Tuberc Lung Dis; 2013 Apr; 17(4):499-504. PubMed ID: 23394127
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Association of CYP2B6 gene polymorphisms and anti-tuberculosis drug-induced hepatotoxicity in a Chinese population.
    Wang Y; Xiang X; Wu SQ; Chen G; Zhang MM; Wang MG; Wang FJ; Sandford AJ; He JQ
    Infect Genet Evol; 2017 Jul; 51():198-202. PubMed ID: 28389387
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Risk factors of isoniazid-induced hepatotoxicity in Tunisian tuberculosis patients.
    Ben Fredj N; Gam R; Kerkni E; Chaabane A; Chadly Z; Boughattas N; Aouam K
    Pharmacogenomics J; 2017 Jul; 17(4):372-377. PubMed ID: 27089936
    [TBL] [Abstract][Full Text] [Related]  

  • 16. NAT2 and CYP2E1 polymorphisms associated with antituberculosis drug-induced hepatotoxicity in Chinese patients.
    An HR; Wu XQ; Wang ZY; Zhang JX; Liang Y
    Clin Exp Pharmacol Physiol; 2012 Jun; 39(6):535-43. PubMed ID: 22506592
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Drug-metabolising enzyme polymorphisms and predisposition to anti-tuberculosis drug-induced liver injury: a meta-analysis.
    Sun F; Chen Y; Xiang Y; Zhan S
    Int J Tuberc Lung Dis; 2008 Sep; 12(9):994-1002. PubMed ID: 18713495
    [TBL] [Abstract][Full Text] [Related]  

  • 18. N-acetyltransferase 2 (NAT2) genotype as a risk factor for development of drug-induced liver injury relating to antituberculosis drug treatment in a mixed-ethnicity patient group.
    Ng CS; Hasnat A; Al Maruf A; Ahmed MU; Pirmohamed M; Day CP; Aithal GP; Daly AK
    Eur J Clin Pharmacol; 2014 Sep; 70(9):1079-86. PubMed ID: 24888881
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Complete sequencing of a genetic polymorphism in NAT2 in the Korean population.
    Lee SY; Lee KA; Ki CS; Kwon OJ; Kim HJ; Chung MP; Suh GY; Kim JW
    Clin Chem; 2002 May; 48(5):775-7. PubMed ID: 11978608
    [No Abstract]   [Full Text] [Related]  

  • 20. Hepatotoxicity during TB treatment in people with HIV/AIDS related to NAT2 polymorphisms in Pernambuco, Northeast Brazil.
    Araujo-Mariz C; Militão de Albuquerque MFP; Lopes EP; Ximenes RAA; Lacerda HR; Miranda-Filho DB; Lustosa-Martins BB; Pastor AFP; Acioli-Santos B
    Ann Hepatol; 2020; 19(2):153-160. PubMed ID: 31734174
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.